Neurizon Therapeutics Achieves Key Milestone in ALS Research
Neurizon® Therapeutics Limited (ASX:NUZ & NUZOA), a clinical-stage biotechnology company focused on treating neurodegenerative disorders, has announced new rodent pharmacokinetic (PK) data demonstrating that its lead compound NUZ-001 and its primary active metabolite, NUZ-001 Sulfone, successfully cross the blood-brain barrier (BBB). This achievement marks …
Team Kalkine |
20 Jun 2025| Read Time : 10 Mins